Renal Cell Carcinoma study: HC-7366 vs Belzutifan
Official title A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
ClinicalTrials.gov ID: NCT06234605
What this study is testing
What is HC-7366?
HC-7366 is an investigational oral medicine being studied as a potential treatment for kidney cancer. is designed to activate a specific protein called GCN2 in the body.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find the safest dose of HC‑7366 when used with belzutifan and to see if it works for patients with advanced or metastatic kidney cancer.
- Who it's for
- It is looking for adults with locally advanced or metastatic kidney cancer that mainly has clear‑cell type, regardless of VHL gene status.
- What's involved
- Participants may receive HC‑7366 alone or with belzutifan, have regular clinic visits, blood tests, and imaging scans to monitor safety and effectiveness.
- Time commitment
- The study lasts about 6–12 months, with multiple visits for dosing, monitoring, and follow‑up tests.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
- Be age 18 years or older (male or female) at the time of consent
The study team makes the final eligibility decision.
Where it is enrolling
- Tucson, Arizona, United States
- La Jolla, California, United States
- Los Angeles, California, United States
- Aurora, Colorado, United States
- Lone Tree, Colorado, United States
- New Haven, Connecticut, United States
- Saint Paul, Minnesota, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Cleveland, Ohio, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Lubbock, Texas, United States
- Fairfax, Virginia, United States
- Seattle, Washington, United States
- Madison, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Tucson, Arizona, United States; La Jolla, California, United States; Los Angeles, California, United States; Aurora, Colorado, United States; Lone Tree, Colorado, United States; New Haven, Connecticut, United States and 10 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.